Clinical Trial Update: Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and pharmacokinetics of Jin Fu Kang in combination with docetaxel for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Jin Fu Kang

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED